Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Li, Yi ^a   Ren, Gang ^a   Wang, Yan Xiang ^a   Kong, Wei Jia ^a   Yang, Peng ^a   Wang, Yue Ming ^a   Li, Ying Hong ^a   Yi, Hong ^a   Li, Zhuo Rong ^a   Song, Dan Qing ^a   Jiang, Jian Dong ^a,b  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; BERBERINE DERIVATIVE; BEROLINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DEMETHYLENEBERBERINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR; JATRORRHIZINE; LOW DENSITY LIPOPROTEIN RECEPTOR; PHENYLALANINE; RECOMBINANT ENZYME; THALIFENDINE; THREONINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ISOENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYDROGEN BOND; LIQUID CHROMATOGRAPHY; LIVER CELL; MALE; MASS SPECTROMETRY; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; UPREGULATION; ANIMAL; BIOTRANSFORMATION; CELL STRAIN HEPG2; CHEMISTRY; DRUG DETOXIFICATION; ENZYMOLOGY; LIVER; METABOLISM; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HEP G2 CELLS; HUMANS; ISOENZYMES; LIVER; MALE; METABOLIC DETOXICATION, PHASE I; RATS; RATS, WISTAR; RECEPTOR, INSULIN; RECEPTORS, LDL;

EID: 79955800843     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-62     Document Type: Article

References (36)

1. Zhao GP. Huanglian. Chinese Materia Medica Dictionary 2006, 2:2815-2820. Shanghai: Science and Technology Press, Zhao GP, 2.
2. Kong WJ, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a Novel Cholesterol-Lowering Drug Working Through a Unique Mechanism Distinct from Stains. Nat Med 2004, 10:1344-1351. 10.1038/nm1135, 15531889.
3. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010, 59:285-292. 10.1016/j.metabol.2009.07.029, 19800084.
4. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, Wang YM, Shan N, Zhou ZX, Yang P, You XF, Li ZR, Si SY, Zhao LX, Pan HN, Jiang JD. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009, 58:109-119. 10.1016/j.metabol.2008.08.013, 19059538.
5. Zhao W, Xue R, Zhou ZX, Kong WJ, Jiang JD. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother 2008, 62:730-731. 10.1016/j.biopha.2008.01.007, 18337056.
6. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G. Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine. J Clin Endocrinol Metab 2008, 93:2559-2265. 10.1210/jc.2007-2404, 18397984.
7. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, Zhao LX, Pan HN, Jiang JD. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 2008, 57:1029-1037. 10.1016/j.metabol.2008.01.037, 18640378.
8. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005, 25:2170-2176. 10.1161/01.ATV.0000181761.16341.2b, 16100034.
9. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264. 10.2337/db06-0006, 16873688.
10. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008, 294:E148-E156. 2464622, 17971514.
11. Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 2006, 34:2064-2072. 10.1124/dmd.106.011361, 16956957.
12. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, Johnson EF. Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2. J Biol Chem 2007, 282:14348-1455. 10.1074/jbc.M611692200, 17311915.
13. Sansen S, Hsu MH, Stout CD, Johnson EF. Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants. Arch Biochem Biophys 2007, 464:197-206. 10.1016/j.abb.2007.04.028, 2773796, 17540336.
14. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, Johnson EF. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-A Resolution. J Biol Chem 2004, 279:35630-35637. 10.1074/jbc.M405427200, 15181000.
15. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, Chenery RJ, Bridges AM. Crystal structure of human cytochrome P450 2D6. J Biol Chem 2006, 281:7614-7622. 10.1074/jbc.M511232200, 16352597.
16. Porubsky PR, Meneely KM, Scott EE. Structures of human cytochrome P450 2E1: insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem 2008, 283:33698-33707. 10.1074/jbc.M805999200, 2586265, 18818195.
17. Ekroos M, Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 2006, 103:13682-13687. 10.1073/pnas.0603236103, 1564212, 16954191.
18. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 2004, 279:38091-38094. 10.1074/jbc.C400293200, 15258162.
19. Szklarz GD, Halpert JR. Molecular basis of P450 inhibition and activation implications for drug development and drug therapy. Drug Metab Dispos 1998, 26:1179-1184.
20. Gotoh O. Cytochrome P450 Family 2 (CYP2) Proteins inferred from Comparative Analyses of Amino Acid and Coding Nucleotide Sequences. J Biol Chem 1992, 267:83-90.
21. Fu DH, Jiang W, Zheng JT, Zhao GY, Li Y, Yi H, Li ZR, Jiang JD, Yang KQ, Wang Y, Si SY. Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening. Mol Cancer Ther 2008, 7:2386-2393. 10.1158/1535-7163.MCT-08-0035, 18723485.
22. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999, 57:465-480.
23. Lu AY, Wang RW, Lin JH. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 2003, 31:345-350. 10.1124/dmd.31.4.345, 12642457.
24. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003, 21:815-832.
25. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998, 26:207-215.
26. Koley AP, Buters JT, Robinson RC, Markowitz A, Friedman FK. Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone. J Biol Chem 1997, 272:3149-3152. 10.1074/jbc.272.6.3149, 9013547.
27. McLaughlin LA, Paine MJ, Kemp CA, Maréchal JD, Flanagan JU, Ward CJ, Sutcliffe MJ, Roberts GC, Wolf CR. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J Biol Chem 2005, 280:38617-38624. 10.1074/jbc.M505974200, 16162505.
28. Guengerich FP, Miller GP, Hanna IH, Sato H, Martin MV. Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps. J Biol Chem 2002, 277:33711-33719. 10.1074/jbc.M205146200, 12093814.
29. Baune B, Furlan V, Taburet AM, Farinotti R. Effect of Selected Antimalarial Drugs and Inhibitors of Cytochrome P-450 3A4 on Halofantrine Metabolism by Human Liver Microsomes. Drug Metab Dispos 1999, 27:565-568.
30. Murphy PJ. The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008. Drug Metab Dispos 2008, 36:1977-1982. 10.1124/dmd.108.023226, 18635745.
31. Qiu F, Zhu Z, Kang N, Piao S, Qin G, Yao X. Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos 2008, 36:2159-2165. 10.1124/dmd.108.021659, 18703644.
32. Li YH, Yang P, Kong WJ, Wang YX, Hu CQ, Zuo ZY, Wang YM, Gao H, Gao LM, Feng YC, Du NN, Liu Y, Song DQ, Jiang JD. Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy. J Med Chem 2009, 52:492-501. 10.1021/jm801157z, 19090767.
33. Li YH, Li Y, Yang P, Kong WJ, You XF, Ren G, Deng HB, Wang YM, Wang YX, Jiang JD, Song DQ. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine. Bioorg Med Chem 2010, 18(17):6422-8. 10.1016/j.bmc.2010.06.106, 20673726.
34. Hua W, Ding L, Chen Y, Gong B, He J, Xu G. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 2007, 44:931-937. 10.1016/j.jpba.2007.03.022, 17531424.
35. Bellosta S, Paoletti R, Corsini A. Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions. Circulation 2004, 109:III50-III7.
36. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. Jama 2004, 291:2821-2827. 10.1001/jama.291.23.2821, 15199031.